Molecular Pharmacology (USA)'s topical anti-inflammatory manufacturing process gets patent

By Angela McDaniels

Seattle, April 19 - Molecular Pharmacology (USA) Ltd. said a new patent has been filed that describes a proprietary process for the manufacture of topical biological secondary injury mediators (B-SIMs), which the company is developing to stop tissue disruption that occurs after injury.

The B-SIMS covered by the patent suppress the body's reactions such as inflammation and damage of otherwise uninjured cells that are triggered in response to an injury, should have local, rather than systemic, effects and may be significantly less expensive to manufacture than conventional B-SIMs, according to a company news release.

The patent was lodged by Cambridge Scientific Pty. Ltd., but Molecular Pharmacology holds a global, exclusive license to manufacture, commercialize, market and distribute topical anti-inflammatory and analgesic products based on the proprietary MPL-TL compound.

The patent, titled "Tissue Disruption Treatment and Composition for Use," will be published in April under U.S. Patent No. 11,218,382, according to the release.

The company said the first conditions targeted by the B-SIMs will be musculoskeletal injuries such as joint inflammation, musculoskeletal pain, overuse and strain injuries, burns and surgical and cosmetic procedures.

Molecular Pharmacology (USA) is a biotechnology company based in Los Angeles that develops analgesic and anti-inflammatory products based on the proprietary MPL-TL compound.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.